Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

romidepsin 5fludarabine phosphate 5Cyclosporine 5Biopsy 5tanespimycin 4Gemcitabine 4belinostat 3aldesleukin 3Vorinostat 3Polymerase Chain Reaction 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Irinotecan 3Flow Cytometry 3Busulfan 3Bortezomib 3B3(Fv)-PE38KDEL recombinant immunotoxin 3Antilymphocyte Serum 3nelarabine 2laromustine 2fludarabine 2entinostat 2alvocidib 2Specimen Handling 2Psychiatric Rehabilitation 2Pharmacogenomic Testing 2O(6)-benzylguanine 2Mycophenolic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, T-Cell, Cutaneous × iratumumab × Clear all
NCT00059995 2013-05-30

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
DermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡